COMPARISON OF ACUTE AND CHRONIC TREATMENT OF VARIOUS SEROTONERGIC AGENTS WITH THOSE OF DIAZEPAM AND IDAZOXAN IN THE RAT ELEVATED X-MAZE

被引:59
作者
WRIGHT, IK
HEATON, M
UPTON, N
MARSDEN, CA
机构
[1] QUEENS MED CTR, SCH MED, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2UH, ENGLAND
[2] SMITHKLINE BEECHAM, MED RES CTR, HARLOW CM19 5AD, ESSEX, ENGLAND
关键词
DIAZEPAM; IDAZOXAN; IPSAPIRONE; RITANSERIN; ONDANSETRON; ACUTE; CHRONIC; WITHDRAWAL; ELEVATED X-MAZE; RAT;
D O I
10.1007/BF02245168
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The aim of this study was to use the elevated X-maze to compare acute and chronic treatments of a 5-HT1A partial agonist, ipsapirone, a 5-HT2 antagonist, ritanserin, and a 5-HT3 antagonist, ondansetron, with those of established anxiolytic (diazepam) and anxiogenic (idazoxan) compounds. Acute diazepam (5 mg/kg IP) produced a significant increase in the percentage open: total entries and time and time spent in the end of the open arms (anxiolytic profile) on the elevated X-maze. Chronic treatment with diazepam (5 mg/kg IP twice daily for 14 days) still produced an anxiolytic profile which was not apparent 24 h after cessation of chronic treatment (withdrawal). In contrast, idazoxan given both acutely (0.25 mg/kg IP) and chronically (0.8 mg/kg/h at a flow rate of 5.5-mu-l/h for 14 days, via osmotic minipumps) resulted in a significant decrease in the percentage open:total entries and time and time spent in the end of the open arms (anxiogenic profile). Acute administration of ipsapirone had no effect on any of the behavioural parameters at doses of 0.01 and 1 mg/kg IP, while 0.1 mg/kg IP produced a significant anxiogenic profile. Chronic treatment with ipsapirone (0.01, 0.1 and 1 mg/kg IP twice daily for 14 days) had no significant effect on rat behaviour on the X-maze but 24 h after ending treatment, ipsapirone at the highest dose used (1 mg/kg) produced a significant anxiogenic profile which was absent when the animals were tested 7 days after cessation of treatment. Ritanserin (0.05 and 0.25 mg/kg IP) had no effect acutely on any of the parameters measured but chronic treatment (0.25 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic effect which was still present 24 h but not 7 days after cessation of treatment. Acute ondansetron (0.01, 0.1 and 1 mg/kg IP) had no effect while chronic ondansetron (0.01 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic profile which was not a result of handling during the chronic dosing schedule, an effect was not measureable 24 h after treatment ended. The results demonstrate that the X-maze can detect anxiolytic activity in non-benzodiazepine drugs, as ritanserin and ondansetron showed anxiolytic profiles but only after chronic treatment. In contrast, the X-maze failed to detect any anxiolytic activity with the 5-HT1A partial agonist ipsapirone after either acute or chronic treatment.
引用
收藏
页码:405 / 414
页数:10
相关论文
共 57 条
[1]  
ABUZZAHAB FS, 1991, P FABRE MON, V4, P185
[2]  
AGHAJANIAN GK, 1987, PSYCHOPHARMACOLOGY 3, P141
[3]   5-HT3 RECEPTORS MEDIATE INHIBITION OF ACETYLCHOLINE-RELEASE IN CORTICAL TISSUE [J].
BARNES, JM ;
BARNES, NM ;
COSTALL, B ;
NAYLOR, RJ ;
TYERS, MB .
NATURE, 1989, 338 (6218) :762-763
[4]   THE ALPHA2-ADRENOCEPTOR ANTAGONIST ACTIVITY OF IPSAPIRONE AND GEPIRONE IS MEDIATED BY THEIR COMMON METABOLITE 1-(2-PYRIMIDINYL)-PIPERAZINE (PMP) [J].
BIANCHI, G ;
CACCIA, S ;
DELLAVEDOVA, F ;
GARATTINI, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 151 (03) :365-371
[5]   CATECHOLAMINE AND 5-HT SYNTHESIS EXVIVO AS AN INDEX OF INVIVO NEURONAL-ACTIVITY AND REGULATION [J].
BROADHURST, AM ;
BRILEY, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (10) :349-351
[6]   THE INFLUENCE OF RITANSERIN, A SEROTONIN ANTAGONIST, IN ANXIETY DISORDERS - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY VERSUS LORAZEPAM [J].
CEULEMANS, DLS ;
HOPPENBROUWERS, MLJA ;
GELDERS, YG ;
REYNTJENS, AJM .
PHARMACOPSYCHIATRY, 1985, 18 (05) :303-305
[7]   NEUROBIOLOGICAL MECHANISMS IN HUMAN ANXIETY - EVIDENCE SUPPORTING CENTRAL NORADRENERGIC HYPERACTIVITY [J].
CHARNEY, DS ;
REDMOND, DE .
NEUROPHARMACOLOGY, 1983, 22 (12B) :1531-1536
[8]   SEROTONIN FUNCTION IN ANXIETY .2. EFFECTS OF THE SEROTONIN AGONIST MCPP IN PANIC DISORDER PATIENTS AND HEALTHY-SUBJECTS [J].
CHARNEY, DS ;
WOODS, SW ;
GOODMAN, WK ;
HENINGER, GR .
PSYCHOPHARMACOLOGY, 1987, 92 (01) :14-24
[9]   ANIMAL-MODELS OF ANXIETY - THE EFFECT OF COMPOUNDS THAT MODIFY 5-HT NEUROTRANSMISSION [J].
CHOPIN, P ;
BRILEY, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (10) :383-388
[10]   EXPLORATION OF MICE IN A BLACK AND WHITE TEST BOX - VALIDATION AS A MODEL OF ANXIETY [J].
COSTALL, B ;
JONES, BJ ;
KELLY, ME ;
NAYLOR, RJ ;
TOMKINS, DM .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1989, 32 (03) :777-785